Skip to main content

Events

Xyzagen’s Christopher Crean Presented Long-Acting Anti-VEGF Research at ARVO 2025 in Salt Lake City
Xyzagen’s Christopher Crean Presented Long-Acting Anti-VEGF Research at ARVO 2025 in Salt Lake City
March 8, 2025

Xyzagen’s Christopher Crean Presented Long-Acting Anti-VEGF Research at ARVO 2025 in Salt Lake City

Xyzagen, Inc., a leading pharmacokinetics consultancy and contract research organization (CRO), announced today the expansion of its laboratory in Pittsboro,…
Read More
Xyzagen, Inc. Highlights Breakthrough Kv7 Channel Opener Chemistry at AES 2024
Xyzagen, Inc. Highlights Breakthrough Kv7 Channel Opener Chemistry at AES 2024
December 16, 2024

Xyzagen, Inc. Highlights Breakthrough Kv7 Channel Opener Chemistry at AES 2024

Xyzagen, Inc., a leading pharmacokinetics consultancy and boutique CRO, presented research on its novel Kv7 channel opener compounds at the American…
Read More
Xyzagen to Present New Kv7 Channel Opener Chemistry at American Epilepsy Society 2024 Annual Meeting
Xyzagen to Present New Kv7 Channel Opener Chemistry at American Epilepsy Society 2024 Annual Meeting
November 13, 2024

Xyzagen to Present New Kv7 Channel Opener Chemistry at American Epilepsy Society 2024 Annual Meeting

Xyzagen’s neurology focused drug development and research team, is proud to announce it’ll be presenting a poster on new Kv7…
Read More
Xyzagen, Inc. Presented Groundbreaking Kv7 Research at Society for Neuroscience Annual Meeting
Xyzagen, Inc. Presented Groundbreaking Kv7 Research at Society for Neuroscience Annual Meeting
October 5, 2024

Xyzagen, Inc. Presented Groundbreaking Kv7 Research at Society for Neuroscience Annual Meeting

Xyzagen, Inc., a pharmacokinetics consultancy and boutique CRO presented its internal Kv7 research programs. The successful presentations on neurological disorders…
Read More
Xyzagen, Inc. Showcases Internal Research at the Society of Neuroscience Annual Meeting, Neuroscience 2024
Xyzagen, Inc. Showcases Internal Research at the Society of Neuroscience Annual Meeting, Neuroscience 2024
September 30, 2024

Xyzagen, Inc. Showcases Internal Research at the Society of Neuroscience Annual Meeting, Neuroscience 2024

Xyzagen, Inc. Showcases Internal Research at the Society of Neuroscience Annual Meeting, Neuroscience 2024 Xyzagen’s Poster Presentations at SfN Poster…
Read More
Xyzagen’s Founder, Christopher Crean, Presented Research on Kv7 Prodrugs at Kv7 Symposium
Xyzagen’s Founder, Christopher Crean, Presented Research on Kv7 Prodrugs at Kv7 Symposium
September 16, 2023

Xyzagen’s Founder, Christopher Crean, Presented Research on Kv7 Prodrugs at Kv7 Symposium

Xyzagen, Inc., a leading pharmacokinetics consultancy and contract research organization (CRO), announced today that its founder, Christopher Crean, presented groundbreaking…
Read More
Xyzagen Presents Spring Discovery’s Research on Disulfiram at ARVO 2023
Xyzagen Presents Spring Discovery’s Research on Disulfiram at ARVO 2023
April 28, 2023

Xyzagen Presents Spring Discovery’s Research on Disulfiram at ARVO 2023

Xyzagen, Inc., a pharmacokinetics consultancy and boutique CRO, unveiled new findings on the repurposing of disulfiram as a potential treatment…
Read More
Xyzagen Presents Research on CPL-01 at ASPET 2023
Xyzagen Presents Research on CPL-01 at ASPET 2023
March 12, 2023

Xyzagen Presents Research on CPL-01 at ASPET 2023

Xyzagen, Inc., a pharmacokinetics consultancy and boutique CRO, in support of Cali Biosciences, presented new findings on CPL-01, a novel…
Read More
Xyzagen, Inc. Presented Promising Kv7 Channel Opener Prodrug Research at American Epilepsy Society Annual Meeting
Xyzagen, Inc. Presented Promising Kv7 Channel Opener Prodrug Research at American Epilepsy Society Annual Meeting
December 15, 2022

Xyzagen, Inc. Presented Promising Kv7 Channel Opener Prodrug Research at American Epilepsy Society Annual Meeting

Xyzagen, Inc., a leading pharmacokinetics consultancy and boutique CRO, presented research on its Kv7 channel opener prodrug program at the…
Read More

News

Xyzagen Expands Team with Strategic Hires, Enhancing Quantitative Medicine and Genomics Capabilities
Xyzagen Expands Team with Strategic Hires, Enhancing Quantitative Medicine and Genomics Capabilities
March 30, 2024

Xyzagen Expands Team with Strategic Hires, Enhancing Quantitative Medicine and Genomics Capabilities

Xyzagen, Inc., a leading pharmacokinetics consultancy and contract research organization (CRO), announced the successful expansion of its team with several…
Read More
Xyzagen Expands Services, Provides Drug Stability Capabilities
Xyzagen Expands Services, Provides Drug Stability Capabilities
February 20, 2024

Xyzagen Expands Services, Provides Drug Stability Capabilities

Xyzagen, Inc., a leading pharmacokinetics consultancy and contract research organization (CRO), expanded its service offerings with the introduction of early…
Read More
Xyzagen Provides Dignify Therapeutics with Strategic Laboratory Solution
Xyzagen Provides Dignify Therapeutics with Strategic Laboratory Solution
January 1, 2024

Xyzagen Provides Dignify Therapeutics with Strategic Laboratory Solution

Xyzagen, Inc., a leading pharmacokinetics consultancy and contract research organization (CRO), has established a collaboration with Dignify Therapeutics to provide…
Read More
Xyzagen Expands Laboratory in Pittsboro and Expands Services into In Vitro ADME Assays
Xyzagen Expands Laboratory in Pittsboro and Expands Services into In Vitro ADME Assays
October 1, 2023

Xyzagen Expands Laboratory in Pittsboro and Expands Services into In Vitro ADME Assays

Xyzagen, Inc., a leading pharmacokinetics consultancy and contract research organization (CRO), announced today the expansion of its laboratory in Pittsboro,…
Read More
Xyzagen Plays Critical Role in the Successful NDA Approval of XDEMVY
Xyzagen Plays Critical Role in the Successful NDA Approval of XDEMVY
July 27, 2023

Xyzagen Plays Critical Role in the Successful NDA Approval of XDEMVY

Xyzagen, a leading provider of drug development solutions, is proud to announce its role in supporting the successful New Drug…
Read More
Xyzagen Expands Expertise with New Team Members and Peptide LC-MS Capabilities
Xyzagen Expands Expertise with New Team Members and Peptide LC-MS Capabilities
July 13, 2023

Xyzagen Expands Expertise with New Team Members and Peptide LC-MS Capabilities

Xyzagen, Inc., a pharmacokinetics consultancy and boutique CRO, is proud to announce growth and new capabilities to further enhance its…
Read More
Xyzagen’s founder and Principal Consultant, Christopher Crean, featured on the cover article for Pharmatech Outlook Bioanalytical Services Edition, November 2020
Xyzagen’s founder and Principal Consultant, Christopher Crean, featured on the cover article for Pharmatech Outlook Bioanalytical Services Edition, November 2020
November 11, 2020

Xyzagen’s founder and Principal Consultant, Christopher Crean, featured on the cover article for Pharmatech Outlook Bioanalytical Services Edition, November 2020

The pharmaceutical drug discovery industry is evolving. Innovations in the sector are more and more powered by seed, NIH, and…
Read More
Xenon Acquires Next-Generation Epilepsy Drug from 1st Order Pharmaceuticals
Xenon Acquires Next-Generation Epilepsy Drug from 1st Order Pharmaceuticals
April 26, 2017

Xenon Acquires Next-Generation Epilepsy Drug from 1st Order Pharmaceuticals

1st Order acquired 1OP2198 from an undisclosed third party, and Xenon will have to honor financial responsibilities under that deal.…
Read More
Xenon Expands Ion Channel Neurology Pipeline with Acquisition of New Potassium Channel Modulator for the Treatment of Epilepsy
Xenon Expands Ion Channel Neurology Pipeline with Acquisition of New Potassium Channel Modulator for the Treatment of Epilepsy
April 26, 2017

Xenon Expands Ion Channel Neurology Pipeline with Acquisition of New Potassium Channel Modulator for the Treatment of Epilepsy

Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical company, today reported the expansion of its ion channel, neurology-focused product pipeline with XEN1101,…
Read More
CONTACT US

Learn How We Can Become Your Virtual Discovery and PK Group

Our team is here to assist. Complete the form and we’ll be in touch shortly.

480 Hillsboro St., Ste 140 Pittsboro, NC 27312

LAB OPERATIONS: 919-726-2072

GENERAL INFO: [email protected]

BUSINESSS DEV: [email protected]

Get in touch

Name(Required)
We are a proud registered supplier of scientist.com